Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.

Britain’s GlaxoSmithKline Plc agreed to pay up to $2 billion to iTeos Therapeutics Inc. to develop and sell a potential cancer treatment together, the companies said on June 14.

The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).

An immunotherapy showed for the first time it can help early-stage lung cancer patients survive longer without their disease returning, according to data on May 19, a potential turning point for such drugs to be used before tumors spread.

An experimental Bristol Myers Squibb drug from a new class of immunotherapy used in combination with the company’s big-selling cancer medicine Opdivo significantly extended the time it took for advanced melanoma to worsen compared with Opdivo alone, according to early data from a study released on May 19.

The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee did not agree in a meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma.

Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.

U.S. Food and Drug Administration Approves Opdivo®(nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma — Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 April 16, 2021 […]

Takeda Pharmaceutical is advancing the Japanese pharma giant’s immune-oncology portfolio through the acquisition of the immunotherapy pioneer Maverick Therapeutics.

AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.